| General Information | |
|---|---|
| ZINC ID | ZINC000096938385 |
| Molecular Weight (Da) | 369 |
| SMILES | O=C(c1ccc2c(c1)c1ccccc1n2Cc1ccccn1)N1CCCCC1 |
| Molecular Formula | C24N3O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 108.599 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 28 |
| LogP | 4.418 |
| Activity (Ki) in nM | 407.38 |
| Polar Surface Area (PSA) | 38.13 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.98445344 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.25 |
| Ilogp | 3.38 |
| Xlogp3 | 4.2 |
| Wlogp | 4.48 |
| Mlogp | 3.4 |
| Silicos-it log p | 4.29 |
| Consensus log p | 3.95 |
| Esol log s | -5.01 |
| Esol solubility (mg/ml) | 0.00357 |
| Esol solubility (mol/l) | 0.00000967 |
| Esol class | Moderately |
| Ali log s | -4.71 |
| Ali solubility (mg/ml) | 0.0072 |
| Ali solubility (mol/l) | 0.0000195 |
| Ali class | Moderately |
| Silicos-it logsw | -7.3 |
| Silicos-it solubility (mg/ml) | 0.0000184 |
| Silicos-it solubility (mol/l) | 4.99E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.57 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.45 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.031 |
| Logd | 3.383 |
| Logp | 4.062 |
| F (20%) | 0.488 |
| F (30%) | 0.013 |
| Mdck | - |
| Ppb | 95.61% |
| Vdss | 1.732 |
| Fu | 1.88% |
| Cyp1a2-inh | 0.833 |
| Cyp1a2-sub | 0.208 |
| Cyp2c19-inh | 0.935 |
| Cyp2c19-sub | 0.072 |
| Cl | 3.42 |
| T12 | 0.197 |
| H-ht | 0.953 |
| Dili | 0.842 |
| Roa | 0.182 |
| Fdamdd | 0.919 |
| Skinsen | 0.174 |
| Ec | 0.003 |
| Ei | 0.036 |
| Respiratory | 0.865 |
| Bcf | 1.336 |
| Igc50 | 4.596 |
| Lc50 | 5.144 |
| Lc50dm | 4.977 |
| Nr-ar | 0.098 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.792 |
| Nr-aromatase | 0.838 |
| Nr-er | 0.251 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.067 |
| Sr-are | 0.583 |
| Sr-atad5 | 0.049 |
| Sr-hse | 0.649 |
| Sr-mmp | 0.416 |
| Sr-p53 | 0.557 |
| Vol | 396.294 |
| Dense | 0.932 |
| Flex | 0.143 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.517 |
| Synth | 2.061 |
| Fsp3 | 0.25 |
| Mce-18 | 56 |
| Natural product-likeness | -1.43 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |